Yvonne Greenstreet
CEO
clinical developmentpharmaceutical strategyrare diseases
Details
- ●Modalities: siRNA, RNAi therapeutics
- ●Therapeutic areas: rare diseases, cardiology, hepatology, nephrology, neuroscience, metabolic
- ●Key targets: TTR, ALAS1, HAO1, glycolate oxidase, PCSK9
- ●Indications: hATTR amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, ATTR cardiomyopathy
- ●Funding: N/A (public since 2004, profitable as of 2025)
Partners & investors
- Public (NASDAQ: ALNY)· Investor
Key considerations
- ●AI tools in use: Proprietary siRNA design algorithms, ML-based sequence optimization platform, Enzymatic ligation manufacturing platform
- ●$250M investment in enzymatic ligation manufacturing (2025)
- ●Computational sequence design for GalNAc-conjugated siRNAs
- ●Alnylam 2030 strategy: 3-4 new IND filings per year through AI-accelerated design
Pipeline
- Phase 12
- Approved4
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)
Key people
Akshay Vaishnaw
President of R&D
RNAi biologyclinical developmentimmunology